PAR 3.77% 25.5¢ paradigm biopharmaceuticals limited..

Ann: Trading Halt, page-76

  1. 739 Posts.
    lightbulb Created with Sketch. 206
    Initially, I also feel a tad negative however, history tells me either way they would have gone into a trading halt, Could be good, could be ok but more than likely not disaster. Prior to CUV announcing their approval from the FDA Oct 9, 2019 they went into a trading halt late on 8 Oct (Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd ACN 089 644 119 (CUV) requests a trading halt with respect to its ordinary shares listed on the Australian Securities Exchange (ASX). The trading halt is requested by CUV pending a material announcement to the market regarding a decision by the US Food and Drug Administration (FDA) on the review of CUV’s New Drug Application (NDA) for marketing approval of SCENESSE® (afamelanotide 16mg) to treat erythropoietic protoporphyria (EPP). The FDA has advised a decision date of 8th October 2019 (US time) to the review of the NDA. The trading halt is necessary as otherwise trading in CUV’s securities might occur whilst the market as a whole is not reasonably informed. CUV requests the trading halt to last until the earlier of CUV releasing an announcement in relation to the outcome to the review process or until the commencement of trade on Friday 11th October 2019. The positive news was release prior to open the next morning 9 Oct. Hope we get good news Monday but could be anything?? GLTA
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
25.5¢
Change
-0.010(3.77%)
Mkt cap ! $89.19M
Open High Low Value Volume
27.0¢ 27.0¢ 25.5¢ $162.7K 620.9K

Buyers (Bids)

No. Vol. Price($)
2 25008 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 34768 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.